Japan's Astellas shows nearly 50% gain in Q1 even as sales drag on price revisions

First quarter financial year core operating profit for Tokyo-based Astellas Pharma reached ¥67.1 billion, up a tad more than 49% even as overall sales dipped on reimbursement price revisions in Japan.

However, the company said in a release that sales of Xtandi (enzalutamide) grew and aided the bottom line along with the transfer of the global dermatology business in April, part of a $727 million deal with Danish specialty product firm LEO last year.

"We are pleased with our solid performance and ability to achieve sustainable growth through increasing sales of Xtandi … and overall (bladder) treatments, new product introductions and focused investment in innovation and strengthening our base,” said Yoshihiko Hatanaka, president and CEO of Astellas.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Overall sales, however, fell nearly 6% in the first quarter ended June 30, compared to the same period a year ago, to ¥337.8 billion.

- here's the release

Related Articles:
British watchdogs suspend Astellas UK after investigations, audits, and a crackdown from Japanese HQ
Drug price cuts in Japan sink in though details sparse
Japan's Astellas eyed to buy Kaketsuken's vaccine business
Astellas' Xtandi under pressure as U.S. lawmakers push for generic swap
Japan's Astellas Pharma gets $727M for ailing dermatology unit as it swings to new areas


Suggested Articles

Perrigo is treading water in its specialty drugs reinvention plan. Could a merger with another struggling drugmaker—à la Pfizer and Mylan—be the cure?

Companies routinely update analysts, but a new SEC order for tiny TherapeuticsMD offers a lesson—or reminder—about when to keep quiet.

AveXis' ex-CSO is "prepared to assert his rights and defend his conduct accordingly," a statement from a lawyer who recently represented Elon…